Pipeline - Trovagene

Providing New Treatment Options Across a
Wide Array of Cancers

Demonstrated synergy of onvansertib in combination with already
approved chemotherapies and targeted therapeutics

We are developing onvansertib as part of a combination regimen across a variety of cancers and integrating a predictive clinical biomarker strategy to identify patients who are most likely to respond to treatment. The opportunity to bring new treatment options to patients in indications where there is a high medical need we believe presents significant market opportunities.

Pipeline within a Molecule™
3 Investigational New Drug (INDs) in place with the FDA
Preclinical
Phase 1
Phase 2
Metastatic Castration-Resistant Prostate (CRPC)
Phase 2 trial in combination with Zytiga® (abiraterone acetate)/prednisone – Ongoing
Metastatic Colorectal (mCRC)
Phase 1b/2 trial in combination with FOLFIRI + Avastin® – Ongoing
Acute Myeloid Leukemia – Orphan Drug Designation in the U.S. and Europe
Phase 2 trial in combination with Decitabine – Ongoing
Myelodysplastic Syndrome
Phase 1b/2 Investigator Initiated Trial (commencing Q1’20)
Ovarian, Breast, Pancreatic, Small-Cell Lung
Phase 1b/2 trial ready (Preclinical Data Available)
Leukemias and Lymphomas
Solid Tumors

Recent News

Dec 9, 2019

Efficacy, Durability of Response and Safety of Onvansertib Demonstrated in Completed Phase 1b Trial in AML Patients Presented in Oral Session at ASH

Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis), for the treatment of various cancers including leukemia, prostate and colorectal, today announced the presentation of final results from…

Dec 4, 2019

Trovagene Announces Data Showing Ability of Onvansertib to Rescue Venetoclax-Resistance in Acute Myeloid Leukemia (AML)

Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis) for the treatment of various cancers including leukemia, prostate and colorectal, today announced new in-vitro and in-vivo data suggesting that onvansertib may provide…

Nov 14, 2019

Trovagene Presents Positive Data in Metastatic Prostate Cancer Phase 2 Trial Showing Clinical Response in Patients Resistant to Zytiga®

Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis), for the treatment of various cancers including prostate, colorectal and leukemia, today announced new positive data from its Phase 2 trial evaluating onvansertib in combination with Zytiga®…